Johnson & Johnson

JNJ

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$665m

Combined value at quarter end

Last quarter

2 bought

5 sold or trimmed

Fund portfolios

Funds holding it

See which

Price at Q3 ’26 end

$264.74

+4.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-10.8%Q4 ’24

+14.7%Q1 ’25

-7.9%Q2 ’25

+21.4%Q3 ’25

+11.6%Q4 ’25

+18.1%Q1 ’26

+3.9%Q2 ’26

+4.2%Q3 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

12Q4 ’23

11Q1 ’24

11Q2 ’24

11Q3 ’24

10Q4 ’24

9Q1 ’25

9Q2 ’25

9Q3 ’25

10Q4 ’25

10Q1 ’26

11Q2 ’26

1Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Johnson & Johnson.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Johnson & Johnson

Yacktman Asset Management	4.0%$320m	$320m	Added +0.8%	53 qtrs
Tweedy, Browne	3.9%$51.2m	$51.2m	Trimmed -8.1%	53 qtrs
Markel Group	1.2%$155m	$155m	Unchanged	53 qtrs
Mairs & Power	1.0%$107m	$107m	Trimmed -27%	53 qtrs
Fairfax Financial Holdings	0.7%$18.6m	$18.6m	Unchanged	53 qtrs
Jensen Investment Management	0.1%$2.2m	$2.2m	Trimmed -9.9%	53 qtrs
Horizon Kinetics	0.0%$3.9m	$3.9m	Trimmed -1.3%	30 qtrs
Matrix Asset Advisors	0.0%$429k	$429k	Unchanged	54 qtrs
Semper Augustus	0.0%$202k	$202k	New	1 qtr
Dodge & Cox	0.0%$5.3m	$5.3m	Unchanged	53 qtrs
Gardner Russo & Quinn	0.0%$282k	$282k	Trimmed -15%	3 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Johnson & Johnson
		Bought or sold				Filing
2 Sep 2026	Schmid TimothyEVP, WW Chair, MedTech	▼ Sold	22,527	$274.74	$6.2m	Form 4
2 Sep 2026	Schmid TimothyEVP, WW Chair, MedTech	▼ Sold	11,070	$274.74	$3.0m	Form 4
17 Aug 2026	Taubert Jennifer LEVP, WWC. Innovative Medicine	▼ Sold	15,000	$263.36	$4.0m	Form 4
13 Aug 2026	Duato JoaquinCEO and Chairman of the Board	▼ Sold	102,315	$261.00	$26.7m	Form 4
13 Aug 2026	Duato JoaquinCEO and Chairman of the Board	▼ Sold	20,976	$262.00	$5.5m	Form 4
6 Aug 2026	Forminard ElizabethEVP, Chief Legal Officer	▼ Sold	9,344	$257.75	$2.4m	Form 4
6 Aug 2026	Forminard ElizabethEVP, Chief Legal Officer	▼ Sold	6,574	$255.93	$1.7m	Form 4
5 Aug 2026	Duato JoaquinCEO and Chairman of the Board	▼ Sold	41,957	$258.06	$10.8m	Form 4
5 Aug 2026	Duato JoaquinCEO and Chairman of the Board	▼ Sold	6,523	$258.74	$1.7m	Form 4
20 Jul 2026	Broadhurst VanessaEVP, Global Corp Affairs	▼ Sold	23,054	$251.27	$5.8m	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: New Jersey
Financial year ends: 3 January
Shares outstanding: 2.41bn at 17 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

2013

2015

$76bn2017

$82bn2019

$79bn2021

$85bn2023

$94bn2025

Johnson & Johnson revenue and net income by year
Year	Revenue	Net income
2025	$94bn	$27bn
2024	$89bn	$14bn
2023	$85bn	$35bn
2022	$80bn	$18bn
2021	$79bn	$21bn
2020	$83bn	$15bn
2019	$82bn	$15bn
2018	$82bn	$15bn
2017	$76bn	$1.3bn
2016	$72bn	$17bn
2015	–	$15bn
2014	–	$16bn
2013	–	$14bn

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Johnson & Johnson, from their latest N-PORT filings.

Funds holding Johnson & Johnson

AMG Yacktman FundYacktman Asset Management	2.7%	$195m	30 Jun 2026
AMG Yacktman Focused FundYacktman Asset Management	2.2%	$68.6m	30 Jun 2026